Protocol Ledger

NCT05646381 · Phase II · RECRUITING

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Interventional Phase II clinical trial protocol NCT05646381 sponsored by Novartis in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-07 Enrollment: 502 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05646381
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)502 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05646381
Protocol FieldVerified Registry Value
NCT IdentifierNCT05646381
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment502 participants (ESTIMATED)
Registered Start Date2024-03-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI